Xolair (omalizumab) is not an immunosuppressant. It works by a fundamentally different mechanism: instead of broadly suppressing immune function, it targets a single molecule called IgE, which drives allergic reactions. This distinction matters because true immunosuppressants increase your risk of infections, while Xolair does not, and may actually improve certain aspects of immune defense.
How Xolair Works
Xolair is a lab-made antibody that binds to free-floating IgE in your bloodstream. IgE is the immune molecule responsible for triggering allergic reactions. When an allergen like pollen or peanut protein enters your body, IgE attaches to the surface of mast cells and basophils (the cells that release histamine and other inflammatory chemicals). Xolair intercepts IgE before it can latch onto those cells, effectively blocking the allergic cascade before it starts.
Importantly, Xolair does not bind to IgE that is already sitting on cell surfaces, so it doesn’t directly activate mast cells or basophils. Over time, the reduction in free IgE also causes the number of IgE receptors on these cells to drop, making them progressively less reactive to allergens. The result is a targeted dampening of allergic responses, not a broad shutdown of immune function.
Why It’s Not an Immunosuppressant
Traditional immunosuppressants, like high-dose corticosteroids or drugs such as methotrexate, work by dialing down the immune system as a whole. That broad suppression is what makes them effective for autoimmune diseases, but it also leaves you more vulnerable to infections.
Xolair does the opposite of what you’d expect from an immunosuppressant. In placebo-controlled clinical trials, omalizumab was not associated with increased susceptibility to viral infections or immunosuppression. In fact, research suggests it may strengthen part of your innate immune response. By pulling excess IgE out of circulation, Xolair frees up a type of immune cell called plasmacytoid dendritic cells, which play a key role in fighting viruses by rapidly producing interferons. In patients with severe allergic asthma, this antiviral response is often impaired because IgE overwhelms those cells. Xolair helps restore it.
One pilot trial tracked patients receiving Xolair every four weeks alongside healthy controls over the same period. The Xolair group actually reported fewer episodes of upper respiratory viral infections than the healthy controls (a median of zero episodes versus one). While this was a small study, it reinforces the point that Xolair does not weaken immune defenses the way immunosuppressants do.
What Xolair Is Approved to Treat
The FDA has approved Xolair for four conditions, all tied to overactive IgE-driven immune responses:
- Moderate to severe allergic asthma in patients 6 and older whose symptoms aren’t controlled by inhaled corticosteroids
- Chronic rhinosinusitis with nasal polyps in adults who haven’t responded well to nasal corticosteroids
- IgE-mediated food allergy in patients 1 year and older, to reduce the severity of allergic reactions from accidental exposure to trigger foods
- Chronic spontaneous urticaria (ongoing hives without a clear trigger) in patients 12 and older who still have symptoms despite antihistamines
The food allergy approval, granted in February 2024, is particularly notable. In a Phase III trial, 36% of patients treated with Xolair alone could tolerate about eight peanuts’ worth of protein plus two other food allergens without a reaction, compared to 19% in a group receiving oral immunotherapy. Xolair doesn’t cure food allergies, but it raises the threshold for accidental exposure, reducing the chance of a serious reaction.
How Treatment Works in Practice
Xolair is given as an injection under the skin, typically every two or four weeks depending on the condition being treated and your body weight and IgE levels. For asthma, your baseline IgE level helps determine the dose. Treatment is generally considered for patients with serum IgE levels between 30 and 1,500 IU/ml, depending on the indication.
Your first several injections need to happen in a healthcare setting because Xolair carries a small risk of anaphylaxis, a severe allergic reaction to the drug itself. After at least three doses with no hypersensitivity reactions, your provider may approve you for self-injection at home using a prefilled syringe, provided you have no history of anaphylaxis and can recognize and treat an allergic reaction if one occurs. The powdered form of the drug is always prepared and given by a healthcare provider.
How It Compares to Steroids
Many people searching whether Xolair is an immunosuppressant are comparing it to oral corticosteroids, which are commonly prescribed for the same conditions. Oral steroids do suppress the immune system broadly, and long-term use carries serious side effects including bone loss, weight gain, high blood sugar, and increased infection risk. Clinical guidelines now recommend using biologic drugs like Xolair specifically to reduce or eliminate reliance on oral steroids in severe asthma and related conditions.
This distinction became especially relevant during the COVID-19 pandemic. Experts noted that patients on biologics like Xolair were not considered immunosuppressed in the way patients on high-dose corticosteroids or traditional immunosuppressants were. Global asthma guidelines encouraged the use of biologics over oral steroids in part because they don’t carry the same immune vulnerability during a pandemic or any infectious disease season.
If you’re currently taking Xolair or considering it, the key takeaway is that it narrows one specific arm of your immune response, the allergic arm, without compromising your body’s ability to fight infections. That’s a meaningful difference from immunosuppression.